4//SEC Filing
Ross Douglas T. 4
Accession 0001493152-22-007209
CIK 0001642380other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 9:29 PM ET
Size
8.0 KB
Accession
0001493152-22-007209
Insider Transaction Report
Form 4
Transactions
- Award
Option to Purchase Common Stock
2022-03-15+100,000→ 100,000 totalExercise: $1.15Exp: 2032-03-15→ Common Stock (100,000 underlying) - Award
Option to Purchase Common Stock
2022-03-15+100,000→ 100,000 totalExercise: $1.15Exp: 2032-03-15→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
- [F2]Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
Documents
Issuer
Oncocyte Corp
CIK 0001642380
Entity typeother
Related Parties
1- filerCIK 0001808413
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 9:29 PM ET
- Size
- 8.0 KB